Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has made a 61.99% comeback from a 12-month low price of $14.81. It was seen 3.54% higher, changing the price to $23.99, when the closing bell rang on 01/11/2019. At recent session, the prices were hovering between $23.03 and $24.2256. This company shares are 49.35% off its target price of $35.83 and the current market capitalization stands at $1.59B. The recent change has given its price a 22.12% lead over SMA 50 and -56.76% deficit over its 52-week high. The stock witnessed 23.03% gains, 0.59% gains and -40.08% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PTLA’s volatility during a week at 6.72% and during a month it has been found around 9.18%.Portola Pharmaceuticals, Inc. (PTLA) Top Holders
Institutional investors currently hold around $1.68 billion or 0% in PTLA stock. Look at its top three institutional owners. Wellington Management Group Llp owns $215.69 million in Portola Pharmaceuticals, Inc., which represents roughly 13.57% of the company’s market cap and approximately 12.81% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 5,618,289 shares of the stock are valued at $134.78 million. The third largest holder is Blackrock Inc., which currently holds $127.33 million worth of this stock and that ownership represents nearly 8.01% of its market capitalization.
At the end of September reporting period, 102 institutional holders increased their position in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by some 12,429,682 shares, 91 decreased positions by 4,197,974 and 32 held positions by 53,571,503. That puts total institutional holdings at 70,199,159 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 4,773,611 shares while 30 institutional investors sold out their entire positions totaling 913,790 shares.Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Insider Trades
Multiple company employees have indulged in significant insider trading. Portola Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Homcy Charles J has sold 64,218 shares of Portola Pharmaceuticals, Inc. (PTLA) in trading session dated Dec. 17, 2018. These shares are worth $1,195,097 and were traded at $18.61 each. The SEC filing shows that Bird Jeffrey W performed a purchase of 390,000 shares. The Director added these shares by way of transaction on Aug. 23, 2018. The company’s shares were assimilated at $25.84 per share worth to an investment of some $10,077,600 on account of Bird Jeffrey W.
CEO, Lis William, sold 5,113 common shares of Portola Pharmaceuticals, Inc. (PTLA) in the open market. In a transaction dated Jun. 06, 2018, the shares were put up for sale at an average price of $45.21, raking in a sum of $231,159. After this sale, 222,035 common shares of PTLA are directly owned by the insider, with total stake valued at $5,326,620.
In the transaction dated Mar. 12, 2018, the great number of shares disposed came courtesy the EVP, CBO; Fu Tao disposed a total of 1,135 shares at an average price of $38.47, amounting to approximately $43,663. The insider now directly owns 18,346 shares worth $440,121.
Several analysts have released their opinion on Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.86 average brokerage recommendation.